Gabriela Gruia, MD
Gabriela Gruia is an oncologist by training with more than 25 years of oncology drug development experience across small molecules, biologics, immunotherapy, and cell and gene therapy. Currently Dr. Gruia is the Founder and Independent Consultant at Gabriela Gruia Consulting LLC. She previously served as Chief Development Officer at Ichnos Sciences, where she oversaw several key functions including Regulatory Sciences, Clinical Operations, Clinical Pharmacology, Biostatistics and Drug Safety. Previous to Ichnos Sciences, Dr. Gruia, was Senior Vice President and Head of Regulatory Affairs for Novartis Oncology, where she was responsible for leading the Worldwide Oncology Regulatory Affairs organization, and worked in close partnership with research collaborators, preclinical development, the development organization and senior management. Prior to that, she held senior roles at Pharmacia/Pfizer and Rhone Poulenc/Aventis, where she designed and conducted Phase I through Phase III clinical trials investigating solid tumour treatments in the metastatic and adjuvant settings.
Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and has a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Centre in Paris, France. She received her training in oncology and haematology from Rene Descartes University in Paris France.
Dr. Gruia is an independent Director of the Boards of Directors for TScan Therapeutics, Molecular Templates, Aprea Therapeutics and Netris Pharma. Dr. Gruia is also a member of the Scientific Advisory Board of Apoliktos Therapeutics.
Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and has a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Centre in Paris, France. She received her training in oncology and haematology from Rene Descartes University in Paris France.
Dr. Gruia is an independent Director of the Boards of Directors for TScan Therapeutics, Molecular Templates, Aprea Therapeutics and Netris Pharma. Dr. Gruia is also a member of the Scientific Advisory Board of Apoliktos Therapeutics.